In summary, patients with primary CNS A-DLBCL may often have a MYC/BCL2 double-expressor and concurrent MYC and BCL2 and/or BCL6 genetic abnormalities, as well as constitutive activation of the NF-κB pathway. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.